Kerry Chester joins Glythera advisory board

Company: Glythera Ltd

Appointee: Kerry Chester


United Kingdom

Glythera Ltd, which is developing antibody-drug conjugates (ADCs), has appointed Professor Kerry Chester to its scientific advisory board. Prof Chester leads the antibody engineering group at the University College London Cancer Institute and has more than 20 years of experience in antibody engineering and phage-display technology, as well as in the manufacture of antibody therapies for clinical trials. Her current projects include the development of antibodies for use as ADCs, chimeric antigen receptors, nano-medicines and cancer imaging agents.

Glythera announced the appointment on 30 April 2018.

Copyright 2018 Evernow Publishing Ltd.